Empowering Patient Independence: SHL Medical Secures $220M to Advance Next-Gen Self-Injection Solutions

SHL Medical, a world-leading provider of advanced self-injection solutions, is proud to announce that it has successfully raised $220 million in new funding. This significant investment underscores the confidence that investors have in SHL Medical’s cutting-edge approach to enhancing patient independence and improving overall wellbeing. With a robust presence across Switzerland, the USA, Sweden, and Taiwan, and a dedicated team of over 5,000 employees, the company’s expertise is firmly established in the realms of autoinjectors and digital healthcare solutions. The funding will be strategically deployed to accelerate the development and commercialization of innovative self-injection systems, reinforcing SHL Medical’s mission to empower patients, providing them with tools that promote a superior quality of life. By leveraging its comprehensive in-house manufacturing capabilities—from design and development to final assembly, labeling, and packaging—SHL Medical is well-positioned to meet the growing demands of the healthcare market. In addition to scaling existing operations, this capital injection will enhance research and development initiatives, enabling the company to pioneer next-generation technologies that further bridge the gap between traditional healthcare and digital innovation. The fresh infusion of capital will also strengthen partnerships with leading pharmaceutical and biotech companies, ensuring that patient-centric solutions continue to evolve in pace with the dynamic landscape of modern healthcare. As SHL Medical looks to the future, this funding marks a transformational step forward in the quest to redefine self-injection and digital healthcare, echoing the company’s enduring commitment to enabling patients’ independence worldwide.